KIAA0101, a key player in cancer cell survival, emerges as a promising therapeutic target beyond a simple proliferation marker.
Background
Cancer cells replicate their genomes, control cell division, and survive in harsh microenvironments. Molecular biologists have focused on proliferating cell nuclear antigen (PCNA), a marker of rapid cancer cell proliferation, and have investigated the role of KIAA0101, a protein that interacts with it. KIAA0101, also known as PCNA clamp-associated factor (PCLAF), aids in DNA replication, DNA damage repair, and genome maintenance. Clinical studies have repeatedly shown that this protein is abnormally overexpressed in most malignant tumors, leading to poor prognosis and drug resistance.
However, previous studies have mainly focused on simple correlation analyses or small-scale retrospective analyses. Research is lacking on how KIAA0101 specifically interacts with signaling pathways in the process of cancer cells becoming resistant to drugs and surviving. In particular, existing transcriptome data lack the precision to distinguish between different isoforms of this protein, which limits the ability to identify the unique impact of specific gene variants on disease progression. To target KIAA0101 for therapeutic purposes, it is essential to first elucidate the underlying molecular mechanisms.
Key Findings
Recent studies combining large-scale transcriptome analysis, single-cell sequencing, and spatial transcriptome analysis have clearly revealed the microenvironmental ecosystem of KIAA0101-high tumors. The analysis shows that tumors with high KIAA0101 expression are not simply characterized by rapid cell division. They exhibit characteristics similar to cancer stem cells and form an immune-excluded environment with blocked immune cell infiltration. In particular, the phenomenon of expelling immune cells from the tumor is likely mediated by an indirect pathway in which KIAA0101 activates the NF-κB and Wnt/β-catenin signaling pathways, leading to an immune-suppressive environment, rather than directly regulating immune checkpoint genes.
Therapeutic strategies are also being developed in various ways. The first strategy aims to develop small-molecule compounds that target the interface between KIAA0101 and PCNA to block their interaction. The principle is to block the interaction with PCNA and reduce the efficiency of DNA replication in cancer cells. The second approach is to use targeted protein degradation techniques, such as PROTAC, to completely eliminate the KIAA0101 protein from cells. The third approach involves the use of RNA interference (RNAi) or CRISPR gene editing systems to block its expression. Finally, the combination of DNA damage response (DDR) inhibitors is proposed as a promising combination therapy.
Significance and Prospects
This mechanistic elucidation demonstrates that KIAA0101 can be an active drug target to overcome drug resistance. It has opened up the possibility of KIAA0101 as a new target beyond a simple marker of cancer cell proliferation. In the future, as drug development progresses, it is likely that a combination therapy using KIAA0101 inhibitors and existing chemotherapeutic agents or targeted therapies will become a standard guideline. However, there are still many challenges to overcome before commercialization. It is necessary to establish a precise detection method that can distinguish between isoforms, and the entire map of proteins that interact with KIAA0101, other than PCNA (Interactome), must be elucidated first. Furthermore, it is essential to verify the efficacy in models with a normally functioning immune system.
Why It Matters
KIAA0101 inhibition technology is expected to contribute significantly to the treatment of patients with refractory cancers. In particular, it is expected to be effective in tumors with limited treatment options and where immune cells cannot penetrate. By blocking KIAA0101 in cancer cells, the DNA repair mechanism is disrupted. In this state, cancer cells become extremely vulnerable to radiation or chemotherapy. In addition, the inhibition of NF-κB activation breaks down the immune barrier around the tumor, which can significantly increase the response rate of immune checkpoint inhibitors that have not been effective in the past.
KIAA0101, also known as proliferating cell nuclear antigen (PCNA) clamp-associated factor (PCLAF), is a small PCNA-interacting protein linking DNA replication, DNA damage tolerance, cell-cycle progression, and genome maintenance. Aberrant KIAA0101 expression occurs across multiple human malignancies and is frequently associated with aggressive clinicopathological features, therapy resistance, and poor survival. Beyond its canonical role as a proliferation-associated PCNA cofactor, emerging evidence obtained from bulk transcriptomics, single-cell sequencing, and spatially resolved analyses suggests that KIAA0101-high tumor states mark proliferative, stem-like, immune-excluded, and treatment-resistant ecosystems. However, research in this field remains limited by descriptive correlations, small retrospective cohorts, isoform-blind assays, and incomplete mechanistic validation. In this review, we synthesize current evidence on the structural features, regulatory networks, cellular functions, disease-specific roles, immune-microenvironmental associations, and translational relevance of KIAA0101 in cancer. We emphasize that its immune-related effects are more plausibly mediated through indirect regulatory routes, including NF-κB- and Wnt/β-catenin-associated programs, rather than through the direct transcriptional control of immune checkpoint genes. We further discuss therapeutic strategies targeting the KIAA0101-PCNA interface, KIAA0101 degradation, RNA interference/CRISPR-based suppression, and rational combinations with DNA damage response inhibitors or approved targeted agents. Future work should prioritize isoform-resolved detection, non-PCNA interactome mapping, immune-competent functional models, and biomarker-driven validation to determine whether KIAA0101 can be advanced from a cancer-associated molecule to a clinically actionable biomarker or therapeutic vulnerability.
KIAA0101 inhibition technology is expected to contribute significantly to the treatment of patients with refractory cancers. In particular, it is expected to be effective in tumors with limited treatment options and where immune cells cannot penetrate. By blocking KIAA0101 in cancer cells, the DNA repair mechanism is disrupted. In this state, cancer cells become extremely vulnerable to radiation or chemotherapy. In addition, the inhibition of NF-κB activation breaks down the immune barrier around the tumor, which can significantly increase the response rate of immune checkpoint inhibitors that have not been effective in the past.